Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 233-296-7 | CAS number: 10108-64-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- no information
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: Deviations from the current test method; some information is lacking. However, useful in ‘weight of evidence’ approach
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- other: short communication
- Title:
- Unnamed
- Year:
- 1 979
Materials and methods
- Principles of method if other than guideline:
- The skin sensitisation potential of the test material was evaluated in two series of guineapig maximisation tests using the test material at a concentrations upto 0.5%.
- GLP compliance:
- not specified
- Type of study:
- guinea pig maximisation test
Test material
- Reference substance name:
- Cadmium chloride
- EC Number:
- 233-296-7
- EC Name:
- Cadmium chloride
- Cas Number:
- 10108-64-2
- Molecular formula:
- CdCl2
- IUPAC Name:
- cadmium(2+) dichloride
- Details on test material:
- water soluble cadmium compound CdCl2; analytical purity
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- not specified
- Sex:
- not specified
- Details on test animals and environmental conditions:
- none
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal and epicutaneous
- Vehicle:
- petrolatum
- Concentration / amount:
- up to 0.5% CdCl2
Challengeopen allclose all
- Route:
- epicutaneous, open
- Vehicle:
- petrolatum
- Concentration / amount:
- up to 0.5% CdCl2
- No. of animals per dose:
- 20
- Details on study design:
- In a first series 20 guinea pigs were utilised in the treated group (CdCl2, analytical purity) and 20 animals treated in the same way with exception of the test substance were foreseen as control group. For intradermal induction, a 0.007% CdCl2 in water and Freund's complete adjuvants was used. For topical application a 5.0% CdCl2 in petrolatum (w/w) was applied.
Solvent : intradermal induction = water; topical application = petrolatum
Three weeks after induction, epicutaneous challenge were given with 0.5% substance in petrolatum, 0.1% and the control sensitised group. Readings were done 24h and 48h after removal of the aluminum test chambers (so called Finn chambers) on the previously shaved flanks.
In the second series, 19 animals were treated and 18 controls were used and the CdCl2 concentration for induction had been raised to 0.05% for intradermal injection and 7.5% CdCl2 for topical application. Challenging concentrations were 0.5%, 0.25% and 0.05% and petrolatum (control). Readings were conducted blind after 24 h and 48 h. - Challenge controls:
- control: petrolatum
- Positive control substance(s):
- no
Study design: in vivo (LLNA)
- Vehicle:
- other: not applicable
- Concentration:
- not applicable
- No. of animals per dose:
- not applicable
- Details on study design:
- not applicable
- Positive control substance(s):
- other: not applicable
- Statistics:
- chi-square test
Results and discussion
- Positive control results:
- not applicable
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- other: challenged group
- Dose level:
- 0.1%
- No. with + reactions:
- 1
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: other: challenged group. Dose level: 0.1%. No with. + reactions: 1.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- other: challenged group
- Dose level:
- 0.1%
- No. with + reactions:
- 1
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: other: challenged group. Dose level: 0.1%. No with. + reactions: 1.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- other: challenged group
- Dose level:
- 0.5%
- No. with + reactions:
- 2
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reaction
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: other: challenged group. Dose level: 0.5%. No with. + reactions: 2.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reaction.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- other: challenged group
- Dose level:
- 0.5%
- No. with + reactions:
- 4
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: other: challenged group. Dose level: 0.5%. No with. + reactions: 4.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 0%
- No. with + reactions:
- 2
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 0%. No with. + reactions: 2.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 0%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- other: sensitized + challenged group
- Dose level:
- 0.1%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: other: sensitized + challenged group. Dose level: 0.1%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- other: sensitized + challenged group
- Dose level:
- 0.1%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: other: sensitized + challenged group. Dose level: 0.1%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- other: sensitized + challenged group
- Dose level:
- 0.5%
- No. with + reactions:
- 2
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: other: sensitized + challenged group. Dose level: 0.5%. No with. + reactions: 2.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- other: sensitized + challenged
- Dose level:
- 0.5%
- No. with + reactions:
- 4
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: other: sensitized + challenged. Dose level: 0.5%. No with. + reactions: 4.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- other: sensitized group
- Dose level:
- 0%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: other: sensitized group. Dose level: 0%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- other: sensitized group
- Dose level:
- 0%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- unspecified skin reactions
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: other: sensitized group. Dose level: 0%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: unspecified skin reactions.
In vivo (LLNA)
Resultsopen allclose all
- Parameter:
- SI
- Remarks on result:
- other: not applicable
- Parameter:
- other: disintegrations per minute (DPM)
- Remarks on result:
- other: not applicable
Any other information on results incl. tables
The first series of experiments showed
the following results in the CdCl2 exposed versus control animals:
24 h readings:
At 0.5% challenge concentration, 2 animals with test reactions in the treated as well as in the control group. At 0.1% challenge concentration, 1 animal reacted in the control group. The control petrolatum challenge gave at 2 positive animals in the control group.
48 h readings:
At 0.5% challenge, 4
animals in the control and 4 animals in the exposed group.
At 0.1% challenge, 1 animal in the control group. In
the control petrolatum challenge, 0 animals in control and treated group.
No further details were given related to the magnitude,severity and type of the skin reactions after challenge(scores are not provided). No second challenge was
performed. The results were compared with the chi-square
test and the differences were reported as non statistically significant.
The second series of experiments gave the following results:
The differences were
observed between the cadmium exposed and the control animals
were not statistically significant at any of the challenge
concentrations for any of the readings.
In the second series, at challenge concentration of 0.5%, three at
24 h and three at 48 h animals reacted in the treated
group compared to one and one in the controls. At challenge
0.25% one at 24 h and one at 48 h control animal reacted and the
same was seen in the treated group. At 0.05% one
at 24 h and
one at 48 h control animal reacted compared to zero animals
at 24 h and one animal at 48 h treated animal. The petrolatum challenge gave a
single one reacting animal within the treated group.
Applicant's summary and conclusion
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information
- Conclusions:
- The test results, although reported by the author as not statistically significant different, do not allow to conclude the absence of sensitising potential of the substance in a standard test system currently used for legal purposes.
- Executive summary:
The skin sensitisation potential of the test material was evaluated by the guineapig maximisation test.
Two series of experiments were carried out with the test material concentrations upto 0.5%. Guinea pigs showed no contact sensitization following intradermal or topical exposure to cadmium chloride at concentrations up to 0.5%.
The test is stated to be performed using the Guinea Pig Maximization Test but at least some deviations from the current regulatory test protocol are noticed. Furthermore the study is only briefly reported, no justification for the used dose levels is given, observation at induction are omitted and the challenge results are provided without grading scores
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
